Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Fortescue vs PLS Group: Which ASX mining share is the better buy? (Fool) +++ PLS GROUP Aktie +3,79%

NANOVIRICIDES Aktie

 >NANOVIRICIDES Aktienkurs 
1.29 EUR    +4.9%    (TradegateBSX)
Ask: 1.28 EUR / 1400 Stück
Bid: 1.24 EUR / 1645 Stück
Tagesumsatz: 1500 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
Aktie über LYNX handeln
>NANOVIRICIDES Performance
1 Woche: +17,5%
1 Monat: +38,1%
3 Monate: -2,2%
6 Monate: +65,4%
1 Jahr: +10,7%
laufendes Jahr: +35,4%
>NANOVIRICIDES Aktie
Name:  NANOVIRICIDES NEW DL-,01
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US6300873022 / A2PSNF
Symbol/ Ticker:  NV3P (Frankfurt)
Kürzel:  FRA:NV3P, ETR:NV3P, NV3P:GR
Index:  -
Webseite:  https://www.nanoviricides..
Profil:  NanoViricides, Inc. is a clinical-stage biopharmaceutical company focused on developing antiviral therapies using its proprietary nanoviricide platform. The company’s current work centers on creating broad-spectrum nanomedicine drugs designed to ta..
>Volltext..
Marktkapitalisierung:  32.88 Mio. EUR
Unternehmenswert:  30.44 Mio. EUR
Umsatz:  -
EBITDA:  -6.91 Mio. EUR
Nettogewinn:  -7.3 Mio. EUR
Gewinn je Aktie:  -0.36 EUR
Schulden:  -
Liquide Mittel:  2.48 Mio. EUR
Operativer Cashflow:  -6.84 Mio. EUR
Bargeldquote:  2.35
Umsatzwachstum:  -
Gewinnwachstum:  10.46%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  NANOVIRICIDES
Letzte Datenerhebung:  07.10.26
>Kennzahlen
Aktien/ Unternehmen:
Aktien: 25.53 Mio. St.
Frei handelbar: 97.51%
Leerverk. Aktien: -
Rückkaufquote: -24.36%
Mitarbeiter: 7
Umsatz/Mitarb.: -
Analysten:
Analystenrating: Strong buy
Kursziel: 320.96%
Bewertung:
KGV: -
KGV lG: -
KUV: -
KBV: 3.72
PEG-Ratio: -
EV/EBITDA: -
Rentabilität:
Bruttomarge: -
Gewinnmarge: -
Operative Marge: -
Managementeffizenz:
Gesamtkaprendite: -87.91%
Eigenkaprendite: -101.46%
>Peer Group
Gesundheit, Lungen- & Atemwegserkrankungen/ -behandlung, Infektionskrankheiten/ Impfstoffentwicklung/ Antibiotika
 
06.10.26 - 14:54
 NanoViricides Presenting at NIBA′s 153rd Investment Conference in Fort Lauderdale, FL October 7, 2026 (Accesswire)
 
SHELTON, CT / ACCESS Newswire / October 6, 2026 / NanoViricides, Inc. (NYSE American:NNVC) ("the Company") is pleased to announce that it will be presenting tomorrow October 7, 2026 at NIBA's 153rd......
29.09.26 - 14:54
 NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Is In Phase II Clinical Trials (Accesswire)
 
SHELTON, CT / ACCESS Newswire / September 29, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Annual Report on Form 10-K for the fiscal year ending Ju......
28.09.26 - 14:54
 Clinical Trial of the Oral Drug NV-387 to Treat Ebola Has Started Enrollment and Dosing of Patients Last Week, Says NanoViricides (Accesswire)
 
SHELTON, CT / ACCESS Newswire / September 28, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announc......
23.09.26 - 14:42
 Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox Has Begun in DRC, Announces NanoViricides (Accesswire)
 
SHELTON, CT / ACCESS Newswire / September 23, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") today announced that the Phase II Clinical Trial of the Company's Novel Broad-Spectrum ......
15.09.26 - 15:30
 Clinical Trial of the Oral Drug NV-387 to Treat Ebola to Start Next Week, Hoping to Reduce Fatalities and Spread, As the Largest Ebola Outbreak is Expanding in ?DR Congo with 48% Crude Fatality Rate, Says NanoViricides (Accesswire)
 
SHELTON, CT / ACCESS Newswire / September 15, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announc......
08.09.26 - 14:42
 NanoViricides: Clinical Trial for an Oral Drug to Treat Ebola is Registered in the Pan African Clinical Trials Database and is Ready to Go, As the Largest Ebola Outbreak Continues to Expand in DR Congo (Accesswire)
 
SHELTON, CT / ACCESS Newswire / September 8, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announce......
31.08.26 - 14:42
 While Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 as A Treatment for Measles (Accesswire)
 
SHELTON, CT / ACCESS Newswire / August 31, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the developmen......
18.08.26 - 14:42
 NanoViricides: The Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the Current Largest Ever and Expanding Ebola Outbreak to Begin Soon (Accesswire)
 
SHELTON, CT / ACCESS Newswire / August 18, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces ......
10.08.26 - 14:42
 NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak (Accesswire)
 
SHELTON, CT / ACCESS Newswire / August 10, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces ......
28.07.26 - 14:42
 NanoViricides Awaits Approval from DR Congo Regulatory Agency for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola, Financing Completed to Support the Trial (Accesswire)
 
SHELTON, CT / ACCESS Newswire / July 28, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces th......
24.07.26 - 14:27
 NanoViricides announces $3.8M registered direct offering; shares down (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
24.07.26 - 14:03
 NanoViricides Announces Pricing of ~$3.8 Million Registered Direct Offering (Accesswire)
 
SHELTON, CT / ACCESS Newswire / July 24, 2026 / NanoViricides, Inc. (NYSE American:NNVC) ("NanoViricides" or the "Company"), a clinical stage, leading global pioneer in the development of broad-spe......
22.07.26 - 14:42
 As Ebola Death Toll Surpasses 930 Within Two Months, NanoViricides Has Applied to the DR Congo Regulatory Agency for Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola (Accesswire)
 
SHELTON, CT / ACCESS Newswire / July 22, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces th......
13.07.26 - 15:39
 As Ebola Spreads in Two More Provinces, NanoViricides Has Received National Ethics Committee Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in Congo (Accesswire)
 
SHELTON, CT / ACCESS Newswire / July 13, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces th......
08.07.26 - 14:42
 Research Analyst Report on NanoViricides Rates Company "Outperform"; Separately, A "Fireside Chat" Interview of the Company′s President Dr. Anil Diwan Hosted by Mr. Dave Donlin was Published by StockInvestor Daily (Accesswire)
 
SHELTON, CT / ACCESS Newswire / July 8, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, reports that ......
06.07.26 - 14:42
 As the Ebola Epidemic Spreads, NanoViricides Advances Towards a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo (Accesswire)
 
SHELTON, CT / ACCESS Newswire / July 6, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, updates that ......
29.06.26 - 14:42
 NanoViricides: US FDA Has Granted A "Rare Pediatric Disease Drug" Designation for NV-387 As A Treatment for Measles - Enables Priority Review Voucher (Accesswire)
 
SHELTON, CT / ACCESS Newswire / June 29, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development ......
22.06.26 - 15:42
 NanoViricides Has Shipped NV-387 Oral Gummies Drug Product for Phase II Clinical Trial to DR Congo (Accesswire)
 
SHELTON, CT / ACCESS Newswire / June 22, 2026 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company") today announced that it has shipped the NV-387 Oral Gummies Drug Product for a Phase II Clinica......
15.06.26 - 14:39
 As the Ebola Epidemic Spreads, NV-387 Oral Gummies Can Enter a Phase II Clinical Trial for Treatment of Ebola - NanoViricides Proposal is Approved by the Pillar Committee in DR Congo (Accesswire)
 
SHELTON, CT / ACCESS Newswire / June 15, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, NanoViricide......
08.06.26 - 14:42
 As the Ebola Emergency Outbreak Grows Rapidly, NanoViricides Has Proposed a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment - with Superior Oral Administration and Escape Resistance Features Over Antibodies (Accesswire)
 
SHELTON, CT / ACCESS Newswire / June 8, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, NanoViricides......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Mann der Arbeit, aufgewacht und erkenne deine Macht. Alle Räder stehen still wenn dein starker Arm es will. - Georg Herwegh
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!